Filing identity and reporting period
The supplied filing is Celsion Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2017, filed May 12, 2017. It does not identify Imunon, Inc.; confirm that this is the intended filing before relying on the figures below.
Celsion was a clinical-stage oncology drug developer. Its lead candidate, ThermoDox, was in Phase III testing for primary liver cancer and Phase II testing for recurrent chest-wall breast cancer; GEN-1 was in an early-stage ovarian cancer trial.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 / comparison |
|---|---|---|
| Licensing revenue | $125,000 | $125,000 |
| Research and development expense | $3.48 million | $3.44 million |
| General and administrative expense | $1.47 million | $1.86 million |
| Operating loss | $4.82 million | $5.18 million |
| Net loss | $5.16 million | $5.72 million |
| Basic and diluted loss per share | $0.12 | $0.24 |
| Cash used in operating activities | $3.13 million | $4.74 million |
Revenue was licensing revenue recognized from a previously received Hisun payment; the filing reports no significant product revenue. Lower G&A and interest expense contributed to the smaller net loss. R&D was slightly higher, principally reflecting increased OPTIMA trial enrollment, treatment, and site-initiation costs. Lower loss per share should be viewed alongside the increase in weighted-average shares to 42.4 million from 23.4 million.
At March 31, cash and cash equivalents were $4.47 million, compared with $2.62 million at year-end; the company had no investment securities remaining. Current assets were $4.61 million and current liabilities $8.84 million, a $4.23 million working-capital deficit. Total liabilities were $24.69 million and stockholders’ equity was $6.11 million. The Hercules secured loan’s remaining principal payments and end-of-term fees, net of debt discounts, totaled $1.47 million and were due in June 2017.
Cash increased by $1.85 million during the quarter: $3.13 million was used in operations, $1.66 million was provided by investment activity (mostly maturity of a certificate of deposit), and $3.32 million was provided by financing. Financing included $4.28 million net proceeds from common-stock and warrant sales and $1.11 million of loan principal payments.
Material changes and financing
On February 14, 2017, Celsion raised approximately $5.0 million gross through a public offering of common shares and warrants. The offering included 19.4 million common shares, Series AA warrants for up to 16.5 million shares, and 2.6 million pre-funded warrants, which were exercised during the quarter. The financing and other warrant exercises expanded the share count; outstanding warrants totaled 35.1 million at quarter-end. The company also reported substantial potential dilution from warrants and equity awards.
Operating cash use was lower than in Q1 2016, while cash on hand remained limited relative to the company’s operating needs. Management said cash and access to its equity facility were expected to fund operations only through the second quarter of 2017; elsewhere, it described cash resources as extending into mid-2017. The filing states there were no committed sources of additional capital. ATM sales were subject to a temporary restriction through June 23, 2017 following the February offering.
Outlook, risks, and other notable items
- Going concern: Management stated that recurring losses and the accumulated deficit raised substantial doubt about the company’s ability to continue as a going concern for the next 12 months. It said that without successful funding and operating measures, available capital would not fund operations for that period. Proposed responses included equity or debt financing, spending reductions, partnerships, collaborations, and out-licensing; success was not assured.
- Clinical and regulatory risk: OPTIMA, a Phase III ThermoDox trial, was expected to complete enrollment in the first half of 2018. That timeline and the candidate’s prospects depend on clinical execution and results. The earlier Phase III HEAT trial failed its primary progression-free-survival endpoint; cited overall-survival findings came from retrospective subgroup analyses and are not definitive proof of benefit. Management expected to complete OVATION enrollment in Q2 2017 and report final clinical and translational data in mid-2017. A Phase II Euro-DIGNITY study was anticipated to begin in the second half of 2017.
- Other risks: Product candidates remained unapproved and development-stage; clinical failure, regulatory delay, manufacturing or supply problems, and the need for further financing could delay or curtail programs. Celsion also cited potential dilution and volatility, and risk of Nasdaq delisting: it had received a minimum-bid-price deficiency notice and reported a May 11, 2017 closing share price of $0.24.
- Contingencies and subsequent events: The $13.47 million EGEN earn-out milestone liability was a Level 3 fair-value estimate and generated a $284,000 non-cash quarterly charge. No legal proceedings were reported. In April 2017, the company amended its office lease, reducing space and rent and extending the lease term; it also provided a one-time cancellation option.
- Controls: Management concluded disclosure controls were effective at a reasonable-assurance level as of March 31, 2017 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing identity: this is a Celsion Corporation filing, not a filing naming Imunon, Inc.
- Assess near-term cash needs against the reported Q2 2017 funding horizon, quarterly operating cash use, and the June 2017 debt payment; verify actual subsequent financing and runway.
- Review the February offering, outstanding warrants, authorized-share capacity, and resulting dilution, including any later equity issuance or ATM sales.
- Track OPTIMA enrollment and results, and distinguish prospective trial evidence from retrospective HEAT subgroup analyses; verify OVATION updates against the filing’s projected milestones.
- Check the status of Nasdaq bid-price compliance and any subsequent listing determination or remediation.